News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
402,318 Results
Type
Article (19557)
Company Profile (307)
Press Release (382448)
Multimedia
Podcasts (82)
Webinars (12)
Section
Business (112027)
Career Advice (444)
Deals (21688)
Drug Delivery (60)
Drug Development (62133)
Employer Resources (52)
FDA (9494)
Job Trends (7682)
News (203315)
Policy (17035)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (1270)
Accelerated approval (24)
Adcomms (18)
Allergies (111)
Alliances (28690)
ALS (149)
Alzheimer's disease (1329)
Antibody-drug conjugate (ADC) (264)
Approvals (9749)
Artificial intelligence (351)
Autoimmune disease (129)
Automation (17)
Bankruptcy (199)
Best Places to Work (6782)
BIOSECURE Act (7)
Biosimilars (121)
Biotechnology (236)
Bladder cancer (132)
Brain cancer (53)
Breast cancer (457)
Cancer (3891)
Cardiovascular disease (309)
Career advice (397)
Career pathing (10)
CAR-T (259)
CDC (14)
Celiac Disease (1)
Cell therapy (660)
Cervical cancer (25)
Clinical research (53905)
Collaboration (1364)
Company closure (2)
Compensation (675)
Complete response letters (48)
COVID-19 (1503)
CRISPR (88)
C-suite (640)
Cystic fibrosis (134)
Data (5393)
Denatured (18)
Depression (114)
Diabetes (340)
Diagnostics (3262)
Digital health (16)
Diversity (5)
Diversity, equity & inclusion (18)
Drug discovery (208)
Drug pricing (97)
Drug shortages (19)
Duchenne muscular dystrophy (225)
Earnings (50508)
Editorial (39)
Employer branding (5)
Employer resources (46)
Events (66236)
Executive appointments (720)
FDA (11982)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (23)
Funding (1170)
Gene editing (188)
Generative AI (29)
Gene therapy (538)
GLP-1 (634)
Government (2065)
Grass and pollen (4)
Guidances (321)
Healthcare (9872)
HIV (41)
Huntington's disease (46)
IgA nephropathy (77)
Immunology and inflammation (212)
Immuno-oncology (44)
Indications (85)
Infectious disease (1675)
Inflammatory bowel disease (169)
Inflation Reduction Act (12)
Influenza (67)
Intellectual property (217)
Interviews (61)
IPO (11603)
IRA (29)
Job creations (1242)
Job search strategy (337)
JPM (45)
Kidney cancer (12)
Labor market (35)
Layoffs (275)
Leadership (14)
Legal (2963)
Liver cancer (65)
Longevity (11)
Lung cancer (508)
Lymphoma (306)
Machine learning (29)
Management (12)
Manufacturing (510)
MASH (145)
Medical device (6476)
Medtech (6505)
Mergers & acquisitions (10987)
Metabolic disorders (922)
Multiple sclerosis (130)
NASH (14)
Neurodegenerative disease (261)
Neuropsychiatric disorders (76)
Neuroscience (2391)
Neurotech (1)
NextGen: Class of 2026 (2967)
Non-profit (1400)
Now hiring (30)
Obesity (427)
Opinion (187)
Ovarian cancer (153)
Pain (156)
Pancreatic cancer (191)
Parkinson's disease (252)
Partnered (18)
Patents (395)
Patient recruitment (418)
Peanut (48)
People (33276)
Pharmaceutical (47)
Pharmacy benefit managers (15)
Phase 1 (18052)
Phase 2 (24464)
Phase 3 (16829)
Pipeline (4293)
Policy (149)
Postmarket research (1273)
Preclinical (7407)
Press Release (36)
Prostate cancer (199)
Psychedelics (50)
Radiopharmaceuticals (258)
Rare diseases (755)
Real estate (2154)
Recruiting (19)
Regulatory (15238)
Reports (24)
Research institute (1258)
Resumes & cover letters (57)
Rett syndrome (27)
RNA editing (21)
RSV (41)
Schizophrenia (134)
Series A (210)
Series B (161)
Service/supplier (2)
Sickle cell disease (92)
Special edition (18)
Spinal muscular atrophy (137)
Sponsored (27)
Startups (2281)
State (1)
Stomach cancer (10)
Supply chain (59)
Tariffs (31)
The Weekly (63)
Vaccines (511)
Venture capital (74)
Weight loss (239)
Women's health (43)
Worklife (6)
Date
Today (14)
Last 7 days (461)
Last 30 days (1496)
Last 365 days (23388)
2026 (2184)
2025 (23684)
2024 (27057)
2023 (29975)
2022 (36152)
2021 (38045)
2020 (34015)
2019 (23991)
2018 (17744)
2017 (19641)
2016 (17036)
2015 (20753)
2014 (15137)
2013 (11197)
2012 (11471)
2011 (12022)
2010 (11392)
Location
Africa (297)
Alabama (70)
Alaska (3)
Arizona (131)
Arkansas (8)
Asia (27672)
Australia (5891)
California (8826)
Canada (2639)
China (917)
Colorado (320)
Connecticut (379)
Delaware (270)
Europe (54065)
Florida (1266)
Georgia (270)
Hawaii (3)
Idaho (22)
Illinois (517)
India (54)
Indiana (281)
Iowa (8)
Japan (322)
Kansas (88)
Kentucky (16)
Louisiana (16)
Maine (53)
Maryland (988)
Massachusetts (6715)
Michigan (152)
Minnesota (366)
Mississippi (3)
Missouri (77)
Montana (21)
Nebraska (10)
Nevada (90)
New Hampshire (62)
New Jersey (2415)
New Mexico (15)
New York (2287)
North Carolina (1102)
North Dakota (7)
Northern California (4317)
Ohio (214)
Oklahoma (12)
Oregon (28)
Pennsylvania (1679)
Puerto Rico (13)
Rhode Island (27)
South America (456)
South Carolina (48)
Southern California (3494)
Tennessee (93)
Texas (1250)
United States (30429)
Utah (186)
Virginia (187)
Washington D.C. (47)
Washington State (774)
West Virginia (3)
Wisconsin (60)
Wyoming (1)
402,318 Results for "antisense therapeutics limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Aperture Therapeutics Announces First-In-Class MMP9 Antisense Oligonucleotide Program for ALS
January 7, 2026
·
3 min read
Rare diseases
Ionis Heads to FDA as Antisense Therapy Aces Pivotal Study in Rare Neurological Disease
By improving gait stability, Ionis’ zilganersen could be “potentially disease modifying,” according to analysts at William Blair.
September 23, 2025
·
2 min read
·
Tristan Manalac
Press Releases
AABB To Run Limited-Time Certified Advanced Biotherapies Professional (CABP) Free Exam Retake Offer
December 1, 2025
·
1 min read
Press Releases
Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers
May 12, 2025
·
6 min read
Press Releases
Haemonetics Acquires Vivasure Medical Limited
January 9, 2026
·
5 min read
Press Releases
YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics
November 24, 2025
·
4 min read
Press Releases
Quiver Bioscience Announces Collaboration with the Dup15q Alliance to Advance Antisense Oligonucleotide Therapeutic Program
March 20, 2025
·
3 min read
Business
Secarna Pharmaceuticals and Orbit Discovery Enter Collaboration to Discover and Develop Peptide-conjugated Targeted Antisense Oligonucleotide Therapeutics
Secarna Pharmaceuticals GmbH & Co. KG and Orbit Discovery Ltd. today announced that they have entered into a collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide (ASO) therapeutics.
May 28, 2024
·
2 min read
Press Releases
Alloy Therapeutics Announces a Target Specific Collaboration and License Agreement for use of AntiClastic™ Antisense Platform with Sanofi
January 8, 2025
·
4 min read
Cardiovascular disease
Ionis’ Tryngolza ‘Game-Changing’ in Lowering Triglycerides, Cementing Case for FDA Filing
Ionis is planning a supplemental submission by the end of the year to expand Tryngolza into severe hypertriglyceridemia. If granted, William Blair expects the antisense drug to be “transformational” for this indication.
November 10, 2025
·
2 min read
·
Tristan Manalac
1 of 40,232
Next
